Ocugen (OCGN) announced that dosing has been successfully completed ahead of schedule in the Phase 2/3 GARDian3 pivotal confirmatory clinical trial for OCU410ST-a modifier gene therapy candidate developed for all Stargardt disease. The OCU410ST Phase 2/3 pivotal confirmatory trial represents Ocugen’s second late-stage clinical program. Ocugen plans to submit the BLA for OCU410ST mid-2027 in alignment with its strategic goal of filing three BLAs by 2028.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OCGN:
- Chardan sees positive read-through to Annexon’s vonaprument from Apellis deal
- Ocugen Updates Roadmap for Gene-Agnostic Retinal Therapies
- Ocugen: Encouraging Phase 2 OCU410 Data in Geographic Atrophy Underpin Buy Rating and Long-Term Upside Potential
- Ocugen price target raised to $12 from $8 at Noble Capital
- Ocugen price target raised to $10 from $7 at H.C. Wainwright